<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03164772</url>
  </required_header>
  <id_info>
    <org_study_id>LUD2014-012-VAC</org_study_id>
    <nct_id>NCT03164772</nct_id>
  </id_info>
  <brief_title>Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With NSCLC</brief_title>
  <official_title>A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ludwig Institute for Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Research Institute, New York City</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>CureVac AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>PharmaJet, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ludwig Institute for Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label multicenter 2-arm study to evaluate the safety and preliminary efficacy&#xD;
      of the addition of a vaccine therapy to 1 or 2 checkpoint inhibitors for NSCLC.&#xD;
&#xD;
      Arm A: mRNA Vaccine [BI 1361849 (formerly CV9202)] + anti-PD-L1 [durvalumab] Arm B: mRNA&#xD;
      Vaccine [BI 1361849] + anti-PD-L1 [durvalumab] + anti-CTLA-4 [tremelimumab]&#xD;
&#xD;
      The run-in evaluation phase is followed by an expansion phase in which the cohort is expanded&#xD;
      to 20 subjects (inclusive of subjects from the run-in).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 20, 2017</start_date>
  <completion_date type="Actual">October 29, 2021</completion_date>
  <primary_completion_date type="Actual">October 29, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>up to 15 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Objective Response Rate at 8 and 24 Weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>24 weeks</time_frame>
    <description>Progression Free Survival (PFS) at 8 and 24 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>up to 15 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">59</enrollment>
  <condition>Metastatic Non-small Cell Lung Cancer</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The run-in dose evaluation phase is followed by an expansion phase in which the cohort is expanded to 20 subjects (including subjects from the run-in).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <description>anti-PD-L1</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>MEDI4736</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tremelimumab</intervention_name>
    <description>anti-CTLA-4</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>BI 1361849</intervention_name>
    <description>mRNA Vaccine</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>CV9202</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          1. Histologic confirmation of metastatic NSCLC. For subjects with known EGFR or ALK/ROS-1&#xD;
             mutations, prior therapy must have included an EGFR tyrosine kinase inhibitor or&#xD;
             ALK/ROS-1 inhibitor, respectively. Subjects may have had 1 prior line of&#xD;
             anti-PD-1/PD-L1 therapy. Subjects who received prior anti-PD-1/PD-L1 therapy must have&#xD;
             progressed during or after treatment, but not prior to Week 12 of treatment.&#xD;
&#xD;
          2. Availability of archival (diagnostic) specimens or willing to undergo a pre-treatment&#xD;
             biopsy.&#xD;
&#xD;
          3. Subjects with treated brain metastases must have been treated with surgery and/or&#xD;
             radiation therapy ≥ 21 days pre-study and must be clinically stable with no&#xD;
             requirement for steroids.&#xD;
&#xD;
          4. Laboratory parameters for vital functions should be in the normal range.&#xD;
&#xD;
          5. ECOG Performance Status ≤ 2.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects may not enter the study if they fulfill any of the following criteria:&#xD;
&#xD;
          1. Treatment with an investigational agent within 4 weeks of starting treatment or prior&#xD;
             treatment with anti-CTLA-4 therapy.&#xD;
&#xD;
          2. Active, suspected or prior documented autoimmune disease, clinically significant&#xD;
             cardiovascular disease, or clinically uncontrolled hypertension.&#xD;
&#xD;
          3. History of pneumonitis or interstitial lung disease, or any unresolved immune-related&#xD;
             adverse events following prior therapy.&#xD;
&#xD;
          4. Major surgery within 4 weeks of starting treatment (or scheduled for surgery during&#xD;
             the projected course of the study) or prior cancer vaccine treatment or allogeneic&#xD;
             bone marrow transplantation.&#xD;
&#xD;
          5. Subjects who are immunosuppressed, including those with known immunodeficiency or have&#xD;
             active infection including tuberculosis or other serious illnesses.&#xD;
&#xD;
          6. Skin disease (e.g., psoriasis) that may prevent intradermal administration of the&#xD;
             vaccine into the target areas.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jhanelle Gray, MD</last_name>
    <role>Study Chair</role>
    <affiliation>H. Lee Moffitt Cancer Center and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Facility</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>May 22, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 24, 2017</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mRNA Vaccine</keyword>
  <keyword>Durvalumab</keyword>
  <keyword>MEDI4736</keyword>
  <keyword>anti-PD-L1</keyword>
  <keyword>tremelimumab</keyword>
  <keyword>anti-CTLA-4</keyword>
  <keyword>BI 1361849</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
    <mesh_term>Tremelimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

